Vaccine for type 1 Diabetes
Type 1 diabetes mellitus (DM)
Type 1 DM can occur at any age group. Although it frequently arises in juveniles, additionally, it may develop in men and women. (See Epidemiology.) Unlike people with type 2 DM, those with type 1 DM will not be obese and usually present in the beginning with diabetic ketoacidosis (DKA). The distinguishing characteristic of a patient with type 1 DM is the fact if his or her insulin is withdrawn, ketosis and finally ketoacidosis develop. Therefore, these patients are dependent on exogenous insulin.
Treatment of type 1 DM requires long term insulin remedy. A multidisciplinary procedure by the medical professional, nurse, and dietitian, with regular specialist consultation, is required to control glycemia, as well as to limit the introduction of its devastating difficulties and manage such complications when they actually occur. Despite the distinctions between type 1 and type 2 DM, the expenses of the two 2 conditions tend to be combined. In a report that focused on type 1 only, Tao et al estimated that in the United States, type 1 DM is responsible for $14.4 billion in medical costs and lost income every year.
Vaccine for type 1 Daibetes
Insulin injected subcutaneously is the first-line treatment of type 1 diabetes mellitus (DM). The different types of insulin vary with respect to onset and duration of action. Short-, intermediate-, and long-acting insulins are available. Short-acting and rapid-acting insulins are the only types that can be administered intravenously (IV). Human insulin currently is the only species of insulin available in the United States; it is less antigenic than the previously used animal-derived varieties.
Articles source: https://emedicine.medscape.com/article/117739-medication#2